Aruna Railkar, PhD, has over 25 years of experience in the pharmaceutical industry, working at the discovery–development interface, providing critical input for progressing compounds into clinical development, prodrug evaluation, understanding challenges in absorption/exposure of lead molecules and development of formulation strategies (conventional or enabling) based on compound properties. During her career at Hoffmann-La Roche, Dr Railkar led the group characterising compounds’ physicochemical and biopharmaceutic properties to inform NCE selection and provided stage-appropriate formulation development for preclinical and clinical studies, collaborating with discovery and development teams in multiple therapeutic areas. Her area of interest is the development of novel dosage forms for existing drugs. She joined Quotient Sciences in 2019.